(Q54285034)

27 May 2018

title

Long-term cyclosporine A treatment of steroid-resistant and steroid-dependent nephrotic syndrome. (English)

1 reference

27 May 2018

1 reference

Melocoton TL

1

1 reference

27 May 2018

Kamil ES

series ordinal

2

1 reference

27 May 2018

Cohen AH

series ordinal

3

1 reference

27 May 2018

Fine RN

series ordinal

4

1 reference

27 May 2018

publication date

1 November 1991

1 reference

27 May 2018

American Journal of Kidney Diseases

published in

1 reference

27 May 2018

volume

18

1 reference

27 May 2018

issue

5

1 reference

27 May 2018

page(s)

583-588

1 reference

27 May 2018

Late resistance to corticosteroids in nephrotic syndrome.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Beneficial effect of second courses of cytotoxic therapy in children with minimal change nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Morphological transition in minimal change nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Treatment of childhood prednisone-resistant nephrotic syndrome and focal segmental glomerulosclerosis with intravenous methylprednisolone and oral alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Relapsing nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Cyclosporine therapy for steroid-resistant nephrotic syndrome. A controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Cyclosporine A induced remission of relapsing nephrotic syndrome in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Cyclosporin in the treatment of idiopathic nephrotic syndrome in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Therapy of focal segmental glomerulosclerosis with cyclosporine A

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Cyclosporin in frequently relapsing minimal change nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

Ciclosporin treatment in children with steroid-dependent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980654-8

7 January 2021

10.1016/S0272-6386(12)80654-8

Identifiers

DOI

1 reference

27 May 2018

1 reference

27 May 2018